Oxford University Innovation (OUI), the research commercialisation arm of the University of Oxford, has appointed Adam Stoten to the newly created position of chief operating officer. Dr Stoten first joined OUI in 2005 as project manager before leaving in 2010 to work at the Oxford-Emergent Tuberculosis Consortium, which conducted the first efficacy study of a new tuberculosis vaccine in infants.
He remained with the spinout until 2013 when he returned to OUI to head up its life sciences commercialisation activities. Dr Stoten received his PhD in immunology from the University of Nottingham.
Oxford University Innovation announced the appointment on 21 March 2017.
Copyright 2017 Evernow Publishing Ltd